GV 143253

Drug Profile

GV 143253

Alternative Names: GV 143253A

Latest Information Update: 04 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Lactams
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 04 Mar 2008 Discontinued - Preclinical for Meticillin-resistant Staphylococcus aureus infections in Italy (Parenteral)
  • 28 Feb 2003 Pharmacokinetics, pharmacodynamics and antimicrobial activity data from a preclinical trial in Methicillin-resistant Staphylococcus aureus infections released by GlaxoSmithKline
  • 16 Apr 1998 Preclinical development for Methicillin-resistant Staphylococcus aureus infections in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top